Pieter R. Cullis, Ph.D., FRSC, FNAI (USA), OC, FRS

His laboratory has been responsible for fundamental advances in the generation, loading and targeting of liposomal systems for intravenous delivery of conventional and genetic drugs. This work has led to two products that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications, one that is in late stage (Phase III) clinical trials and two more that are about to enter Phase I studies. From 1987 to 1991, Dr. Cullis was President and Director of The Canadian Liposome Company Inc. (CLC), a company he co-founded. CLC was a subsidiary of The Liposome Company Inc. (TLC, Princeton , NJ ). Dr. Cullis has also played a founding role in Inex Pharmaceuticals Corp. (Director and CSO 1992-2004), Lipex Biomembranes Inc. (Director and Chairman, 1985-2000), Northern Lipids Inc. (Director and Chairman, 2005 onwards) and Protiva Biotherapeutics Ltd. (Director 2001-2005 and Chairman, Scientific Advisory Board). He has published over 300 scientific articles and is an inventor on over 30 patents.